47
Growth Score
pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
785241
Respiratorius AB (publ) is the developer of new effective drugs for cancer, chronic obstructive pulmonary disease (COPD) and severe asthma
- Johan Drott: CEO
About the Company
Respiratorius AB develops new effective drugs for cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. The company also runs a project within PET imaging with application in cardiovascular diagnostics.
The company is currently conducting clinical development of a drug project (VAL-001), for the treatment of Diffust Large Cell B
cell lymphoma. In COPD and asthma, Respiratorius has focused on a new class of patent-pending drug substances, which compared to existing therapies have a superior ability to relax the small airways. The substances, which utilize a new mechanism of action, have been developed via ex-vivo experiments on human lung tissue in the company's proprietary measuring and testing chamber.
